Zantac Kidney Cancer

Zantac and other ranitidine medications have received a lot of press lately. In April of 2020, the Federal Drug Administration (FDA) withdrew all Zantac and generic equivalents from the market due to detection of the dangerous contaminate NDMA (N-Nitrosodimethylamine). One of the negative effects associated with NDMA is kidney cancer.

NDMA

NDMA is considered a probable carcinogen by a variety of noted national and international health organizations, which means that it probably causes cancer. One of the cancers associated with NDMA is kidney cancer.

The Zantac/NDMA Connection

The connection between Zantac and NDMA was initially identified by an online drugstore that – in its commitment to consumer safety – found NDMA in the popular heartburn and GERD medication, Zantac (and other ranitidine products) in the spring of 2019. Since this discovery, some pharmaceutical companies initiated recalls of the medications, and many large drugstore chains pulled the drugs from their shelves. The FDA took several more months before it implemented its market withdrawal of Zantac and its generics.

Kidney Cancer

Kidney cancer begins in the kidneys, and according to the Mayo Clinic, it is often asymptomatic in the early stages, which makes it more difficult to detect and, consequently, more difficult to adequately treat. The symptoms associated with kidney cancer in the later stages include:

• Blood in one’s urine
• Intermittent fever
• Pain in one’s back or side that doesn’t let up
• Unintentional weight loss
• Loss of appetite
• Exhaustion

Share Your Concerns with an Experienced Drug Injury Attorney

If you used Zantac regularly and now have Kidney cancer, you need a dedicated drug injury attorney on your side.